{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:59:04Z","timestamp":1777895944714,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bbrc.2026.153774","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:47:19Z","timestamp":1776282439000},"page":"153774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chondroitinase ABC enhances trastuzumab activity via cell-surface chondroitin sulfate cleavage in pancreatic cancer cells"],"prefix":"10.1016","volume":"818","author":[{"given":"Masao","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153774_bib1","doi-asserted-by":"crossref","first-page":"eadg3840","DOI":"10.1126\/scitranslmed.adg3840","article-title":"The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets","volume":"16","author":"Sleeboom","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.153774_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.751311","article-title":"The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies","volume":"11","author":"Perez","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.153774_bib3","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.153774_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.153774_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.639666","article-title":"Glycosaminoglycan-protein interactions and their roles in human disease","volume":"8","author":"Shi","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbrc.2026.153774_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114339","article-title":"Exploring the sulfate patterns of chondroitin sulfate\/dermatan sulfate and keratan sulfate in human pancreatic cancer","volume":"205","author":"Ren","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbrc.2026.153774_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0925-4439(00)00051-X","article-title":"Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition","volume":"2","author":"Theocharis","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2026.153774_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1091-255X(01)80025-1","article-title":"Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (Herceptin)","volume":"5","author":"B\u00fcchler","year":"2001","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.bbrc.2026.153774_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"6","author":"Harder","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.153774_bib10","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"11","author":"de Vries","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2026.153774_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1471-2407-13-444","article-title":"Heparan sulfate mediates trastuzumab effect in breast cancer cells","volume":"13","author":"Suarez","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2026.153774_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"2","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.153774_bib13","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ejca.2007.08.018","article-title":"Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer","volume":"16","author":"P\u00e1lyi-Krekk","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.153774_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-015-3414-3","article-title":"CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells","volume":"3","author":"Boulbes","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2026.153774_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1083\/jcb.128.4.673","article-title":"Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon","volume":"4","author":"Jackson","year":"1995","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.153774_bib16","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/carcin\/bgu112","article-title":"A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes","volume":"8","author":"Inagawa","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbrc.2026.153774_bib17","first-page":"576","article-title":"Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates","volume":"6","author":"Fujii","year":"2021","journal-title":"Explor Target Antitumor Ther."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26005383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26005383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:09:27Z","timestamp":1777622967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26005383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"alternative-id":["S0006291X26005383"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153774","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chondroitinase ABC enhances trastuzumab activity via cell-surface chondroitin sulfate cleavage in pancreatic cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153774"}}